Filtered By:
Management: Funding
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 373 results found since Jan 2013.
Food allergy drug developer Alladapt raised $119M in new funding
A developer of a drug designed to treat a variety of food allergies raised $119 million as it prepares for a potentially pivotal clinical trial.
Alladapt Immunotherapeutics Inc. announced the new funding deal Wednesday. Patient Square Capital's Enavate Sciences unit led the round. Founding investor Gurnet Point Capital and new investors AllerFund, Novartis AG, Red Tree Venture Capital and WestRiver Group participated in the deal.
The Menl o Park company had previously raised a total of $63 million…
Source: bizjournals.com Health Care:Physician Practices headlines - June 22, 2022 Category: American Health Authors: Ron Leuty Source Type: news
Top Local Changemakers Addressing Health Equity Gaps Across the U.S. Named Johnson & Johnson Health Equity Innovation Challenge Awardees
NEW BRUNSWICK, N.J., June 14, 2022 – After an extensive search for the top changemakers in six key U.S. cities, Johnson & Johnson today announced the 14 awardees of its Health Equity Innovation Challenge. The awardees, who possess lived experience and a deep understanding of the communities they serve, were selected for their work in generating solutions to help close racial health and mortality gaps in six cities where Black and Brown individuals experience significant health inequities: Chicago, Detroit, Los Angeles, New Orleans, New York City and Philadelphia.The Health Equity Innovation Challenge was created by J...
Source: Johnson and Johnson - June 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
White House Ready to Vaccinate Children Younger Than 5 White House Ready to Vaccinate Children Younger Than 5
A White House confident they have enough doses of vaccine to meet initial demand for the youngest Americans also remains concerned about funding for future resources to fight COVID-19.WebMD Health News
Source: Medscape Allergy Headlines - June 9, 2022 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
News at a glance: China ’s carbon pledge, ARPA-H’s interim head, and an exascale computer
Some content has been removed for formatting reasons. Please view the original article for the best reading experience.
Table of contents
A version of this story appeared in Science, Vol 376, Issue 6597.
Download PDF
CONSERVATION
U.S. moves to stop Alaska copper mine
The U.S. Environmental Protection Agency (EPA) is moving to block construction of a massive copper and gold mine that would risk polluting the headwaters of Alaska’s Bristol Bay, home to the world’s largest sockeye salmon runs. EPA announced last week it plans to forbid dis...
Source: Science of Aging Knowledge Environment - June 2, 2022 Category: Geriatrics Source Type: research
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
Lancet Respir Med. 2022 May 23:S2213-2600(22)00088-1. doi: 10.1016/S2213-2600(22)00088-1. Online ahead of print.ABSTRACTBACKGROUND: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to mechanical ventilation or death in hospitalised patients with COVID-19.METHODS: In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites)...
Source: Respiratory Care - May 26, 2022 Category: Respiratory Medicine Authors: Cameron R Wolfe Kay M Tomashek Thomas F Patterson Carlos A Gomez Vincent C Marconi Mamta K Jain Otto O Yang Catharine I Paules Guillermo M Ruiz Palacios Robert Grossberg Michelle S Harkins Richard A Mularski Nathaniel Erdmann Uriel Sandkovsky Eyad Almasri Source Type: research
Tim Kaine Refuses to Let Long COVID Be an Afterthought
When Virginia Sen. Tim Kaine came down with a “blizzard” of allergy-like symptoms in March 2020, he blamed the layer of pollen coating his car. “It was Washington, D.C., in late March,” he says. I thought, “‘Okay, well, this is hay fever gone wild.’”
Only when his wife, Anne Holton, developed “textbook” COVID-19 symptoms did Kaine start to wonder if he might have the new virus, the subject of the massive economic assistance bill—the CARES Act—that he and other lawmakers were then working to pass. Testing at that time was hard to come by, even for Hill...
Source: TIME: Health - May 4, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 feature Source Type: news
Next US Booster Campaign Faces Delays, Lack of Funds Next US Booster Campaign Faces Delays, Lack of Funds
The Biden administration is also struggling to get funding from Congress to pay for ongoing coronavirus initiatives.WebMD Health News
Source: Medscape Allergy Headlines - March 28, 2022 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
With All Eyes on BA.2, Here ’s What Experts Say Might Happen in the U.S.
For the last two years, the U.S. has been stuck in a cycle of COVID-19 case spikes and lulls. Cases rise dramatically, then drop off—and the process repeats.
Several times, these surges have been preceded by rising case rates in Europe—such as before last year’s Delta wave and the start of last winter’s Omicron spike—which is why experts have been carefully monitoring a recent increase in cases there. More than 5.2 million COVID-19 infections were reported across Europe during the week ending March 20, according to World Health Organization data, and countries including the U.K. have also repo...
Source: TIME: Health - March 25, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
With All Eyes on BA.2, Here ’ s What Experts Say Might Happen in the U.S.
For the last two years, the U.S. has been stuck in a cycle of COVID-19 case spikes and lulls. Cases rise dramatically, then drop off—and the process repeats.
Several times, these surges have been preceded by rising case rates in Europe—such as before last year’s Delta wave and the start of last winter’s Omicron spike—which is why experts have been carefully monitoring a recent increase in cases there. More than 5.2 million COVID-19 infections were reported across Europe during the week ending March 20, according to World Health Organization data, and countries including the U.K. have also repo...
Source: TIME: Health - March 25, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Fauci Warns of Potential Rise in U.S. COVID-19 Cases as Funding Runs Dry
The U.S. could soon see Covid-19 cases rise again and vulnerable people are likely to need a fourth vaccine dose, one of President Joe Biden’s top health advisers warned as the White House calls for more money to fight the pandemic.
Anthony Fauci, the longtime head of the National Institute of Allergy and Infectious Diseases and a Biden adviser, said U.K. officials are already warning him of an increase there driven by the BA.2 sub-variant, easing restrictions and waning protection from vaccines, and that the U.S. tends to be a few weeks behind case curves in the U.K.
[time-brightcove not-tgx=”true”]
&ldq...
Source: TIME: Health - March 18, 2022 Category: Consumer Health News Authors: Josh Wingrove / Bloomberg Tags: Uncategorized COVID-19 healthscienceclimate News Desk wire Source Type: news
Depression, Suicidal Ideation Still Plague Physicians: Survey Depression, Suicidal Ideation Still Plague Physicians: Survey
Historic legislation aims to improve physician mental health by removing barriers to treatment and funding suicide prevention campaigns.Medscape Medical News
Source: Medscape Allergy Headlines - March 4, 2022 Category: Allergy & Immunology Tags: Family Medicine/Primary Care News Source Type: news
NIDCR's Spring 2022 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Spring 2022 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities & Related Notices
NIH/HHS News
Subscribe to NIDCR News
Science Advances
NIDCR News
NIH & NIDCR Release “Oral Health in America: Advances and Challenges”
In December, NIDCR announced the release of a report that provides a comprehensive snapshot of oral health in America, detailing 20 years of advances and challenges and drawing on data from public research and evidence-based practices. For more ...
Source: NIDCR Science News - March 3, 2022 Category: Dentistry Source Type: news
10 Black Americans Who Have Led COVID-19 Response
By The Editorial Team,
IntraHealth InternationalFebruary 22, 2022Meet 10 Black American leaders who are shaping local and national COVID-19 response. These scientists, researchers, policymakers, teachers, and more have seen first-hand how the pandemic exacerbates racial disparities in health. In the US, Black Americans have died from COVID-19 at1.4 times the rate of white people.Today we’re highlighting these leaders as they work to protect their communities and inform our global response to the pandemic.Christopher BarnesAssistant professor, Department of Biology at Stanford UniversityWhen COVID-19 began, Bar...
Source: IntraHealth International - February 17, 2022 Category: International Medicine & Public Health Authors: kseaton Tags: COVID-19 Health Workers Source Type: news
Ebola vaccine being used in Congo produces lasting antibody response, study finds
FINDINGSA new study by UCLA researchers and colleagues demonstrates that the Ebola vaccine known as rVSV ΔG-ZEBOV-GP results in a robust and enduring antibody response among vaccinated individuals in areas of the Democratic Republic of Congo that are experiencing outbreaks of the disease. Among the more than 600 study participants, 95.6% demonstrated antibody persistence six months after they received the vaccine.The study is the first published research examining post –Ebola-vaccination antibody response in the DRC, a nation of nearly 90 million. While long-term analyses of the study cohort continue, the findings will ...
Source: UCLA Newsroom: Health Sciences - February 8, 2022 Category: Universities & Medical Training Source Type: news
